No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 767 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR The 10-year cancer plan: is improving cancer survival still a priority... December 8, 2022 Καρκίνος οισοφάγου January 22, 2019 Keeping progress in oncology on the agenda: ESMO honours recipients of... December 3, 2020 Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... January 9, 2024 Load more HOT NEWS “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... New Safety Signal for Use of Ibrutinib in Combination with Rituximab... Cancer Control in American Indian and Alaska Native Populations: A Conversation... Research with integrity – the importance of communication
